相关实验视频

Updated: Jan 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

提高 PARP 抑制剂在卵巢癌中的疗效:针对 PI3K/AKT/mTOR 途径

Yixuan Wang¹, Qing Xia², Xinjia Wang¹

¹Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.

Journal of ovarian research

|December 11, 2025

概括

将PI3K/AKT/mTOR抑制剂与PARP抑制剂相结合显示出治疗卵巢癌的前景. 这种策略可以克服耐药性并改善结果,特别是在BRCA野生型瘤中.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

卵巢癌是一种致命的恶性瘤,通常是晚期诊断的,并且耐药.
聚 (ADP-ribose) 聚合酶 (PARP) 抑制剂有利于具有同源重组缺陷的瘤 (例如BRCA突变).
帕尔P抑制剂的临床疗效在同类重组能力或BRCA野生类型卵巢癌中是有限的.

研究的目的:

审查结合PI3K/AKT/mTOR途径抑制剂与卵巢癌中PARP抑制剂的证据.
探索克服对PARP抑制剂耐药性的策略.
要突出PI3K/AKT/mTOR轴在调节PARP抑制剂敏感性的作用.

主要方法:

对临床前和临床研究的全面审查.
对PI3K/AKT/mTOR通路的天然和合成抑制剂的检查.
对基于纳米技术的配送系统进行组合治疗的分析.
评估基于生物标志物的临床试验数据.

主要成果:

在卵巢癌中,PI3K/AKT/mTOR通路经常受到失调,并影响PARP抑制剂的敏感性.
与PARP抑制剂共同向PI3K/AKT/mTOR可以在临床前模型中增强抗瘤效果.
纳米技术和分子分层显示出克服抗性的潜力.
组合策略正在临床试验中进行研究.

结论:

将PI3K/AKT/mTOR抑制与PARP阻断相结合是治疗卵巢癌的一个有前途的策略.
这种结合方法可能会扩大PARP抑制剂的治疗应用.
通过在卵巢癌治疗中准这种途径,预计会改善临床结果.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...